Johnson & Johnson (JNJ)vsNeurogene Inc (NGNE)
JNJ
Johnson & Johnson
$229.85
+1.10%
HEALTHCARE · Cap: $547.28B
NGNE
Neurogene Inc
$26.48
-3.53%
HEALTHCARE · Cap: $422.41M
Smart Verdict
WallStSmart Research — data-driven comparison
JNJ leads profitability with a 21.8% profit margin vs 0.0%. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
NGNE
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-43.5%
Fair Value
$160.13
Current Price
$229.85
$69.72 premium
Intrinsic value data unavailable for NGNE.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Reasonable price relative to book value
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : NGNE
The strongest argument for NGNE centers on Price/Book.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : NGNE
The primary concerns for NGNE are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
JNJ profiles as a mature stock while NGNE is a value play — different risk/reward profiles.
NGNE carries more volatility with a beta of 1.89 — expect wider price swings.
JNJ is growing revenue faster at 9.9% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 31/100), backed by strong 21.8% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Neurogene Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Neurogene Inc. is a pioneering biotechnology firm specializing in the development of groundbreaking gene therapies aimed at addressing rare neurological disorders. With a focus on leveraging cutting-edge genetic medicine technologies, the company is committed to creating transformative treatments that meet significant unmet medical needs. Neurogene's robust pipeline of proprietary programs, coupled with its experienced leadership team, emphasizes its dedication to advancing the field of genetic therapies. As the company navigates its clinical development phases, it is well-positioned to enhance the quality of life for patients and families affected by genetic diseases.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?